DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
compose your message
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Siklos (hydroxyurea) now available through ProCare Pharmacy Care’s Siklos At Home program
Medunik USA announced today that Siklos® (hydroxyurea), the first and only hydroxyurea-based treatment FDA-approved for pediatric patients with sickle cell anemia, is now available through the Siklos At Home™ program.
“The recent launch of Siklos® represents an important milestone in Medunik USA’s mission to support patients with rare diseases – in this case, sickle cell anemia,” said Dean Hopkins, the company’s General Manager. “We are looking forward to introducing this treatment to pediatric patients with sickle cell anemia and committed to providing Siklos® at the lowest possible cost to all patients, whether they are cash-paying or have commercial or Medicaid healthcare coverage, through the Siklos At Home™ program, offered through our specialty pharmacy, ProCare Pharmacy Care.”
Through Siklos At Home™, commercially insured patients can receive Siklos® for as little as $0 copay per prescription. Patients who are not insured or whose insurance does not cover Siklos® can pay as little as $99 for 60 tablets or $149 for 90 tablets.
education & researchHydroxyurea Use and Outcomes of Pregnancy in Sickle Cell DiseaseBackground: Hydroxyurea reduces pain cr...
education & researchPhase 3 Study of L-Glutamine Therapy in Sickle Cell Anemia and Sickle ß0-Thalassemia Subgroup Analyses Show Consist...Background: Sickle cell disease (SCD) is...
videos & visualsHydroxyurea and Sickle Cell Disease: A HRSA EMBRACE Projecthttps://www.youtube.com/watch?v=AyMP3P9E...
videos & visualsDon’t Let Sickle Cell Disease Limit Youhttps://www.onescdvoice.com/wp-content/u...
news & eventsPediatric sickle cell study stopped early due to positive resultsA national sickle cell disease study inv...
news & eventsSCD Patients Receiving Hydroxyurea in the U.S. Still Face Many ChallengesPeople with sickle cell disease (SCD) tr...
videos & visualsHydroxyurea: The Best Hope for Sickle Cell Anemia Patientshttps://www.youtube.com/watch?v=L_xSgQWj...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.